Cingulate (CING) Competitors $3.33 -0.29 (-8.01%) Closing price 04:00 PM EasternExtended Trading$3.34 +0.00 (+0.15%) As of 04:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock CING vs. VHAQ, PYRGF, ACHL, ASRT, PDSB, RPTX, IMMX, MGX, ADVM, and GANXShould you be buying Cingulate stock or one of its competitors? The main competitors of Cingulate include Viveon Health Acquisition (VHAQ), PyroGenesis Canada (PYRGF), Achilles Therapeutics (ACHL), Assertio (ASRT), PDS Biotechnology (PDSB), Repare Therapeutics (RPTX), Immix Biopharma (IMMX), Metagenomi (MGX), Adverum Biotechnologies (ADVM), and Gain Therapeutics (GANX). These companies are all part of the "pharmaceutical products" industry. Cingulate vs. Viveon Health Acquisition PyroGenesis Canada Achilles Therapeutics Assertio PDS Biotechnology Repare Therapeutics Immix Biopharma Metagenomi Adverum Biotechnologies Gain Therapeutics Viveon Health Acquisition (NYSE:VHAQ) and Cingulate (NASDAQ:CING) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their profitability, community ranking, media sentiment, institutional ownership, valuation, dividends, risk, analyst recommendations and earnings. Which has more volatility and risk, VHAQ or CING? Viveon Health Acquisition has a beta of -0.1, meaning that its share price is 110% less volatile than the S&P 500. Comparatively, Cingulate has a beta of -0.88, meaning that its share price is 188% less volatile than the S&P 500. Which has better earnings and valuation, VHAQ or CING? CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViveon Health AcquisitionN/AN/A-$610KN/AN/ACingulateN/AN/A-$23.53M-$8.48-0.43 Does the MarketBeat Community believe in VHAQ or CING? Cingulate received 12 more outperform votes than Viveon Health Acquisition when rated by MarketBeat users. CompanyUnderperformOutperformViveon Health AcquisitionN/AN/ACingulateOutperform Votes1275.00% Underperform Votes425.00% Do insiders & institutionals believe in VHAQ or CING? 22.1% of Viveon Health Acquisition shares are owned by institutional investors. Comparatively, 41.3% of Cingulate shares are owned by institutional investors. 75.3% of Viveon Health Acquisition shares are owned by insiders. Comparatively, 17.1% of Cingulate shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Do analysts rate VHAQ or CING? Cingulate has a consensus price target of $25.75, indicating a potential upside of 611.33%. Given Cingulate's stronger consensus rating and higher probable upside, analysts clearly believe Cingulate is more favorable than Viveon Health Acquisition.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viveon Health Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Cingulate 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is VHAQ or CING more profitable? Viveon Health Acquisition's return on equity of 0.00% beat Cingulate's return on equity.Company Net Margins Return on Equity Return on Assets Viveon Health AcquisitionN/A N/A N/A Cingulate N/A -570.20%-236.15% Does the media favor VHAQ or CING? In the previous week, Cingulate had 7 more articles in the media than Viveon Health Acquisition. MarketBeat recorded 7 mentions for Cingulate and 0 mentions for Viveon Health Acquisition. Cingulate's average media sentiment score of 0.51 beat Viveon Health Acquisition's score of 0.00 indicating that Cingulate is being referred to more favorably in the news media. Company Overall Sentiment Viveon Health Acquisition Neutral Cingulate Positive SummaryCingulate beats Viveon Health Acquisition on 7 of the 12 factors compared between the two stocks. Get Cingulate News Delivered to You Automatically Sign up to receive the latest news and ratings for CING and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CING vs. The Competition Export to ExcelMetricCingulatePharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.18M$6.54B$5.42B$8.48BDividend YieldN/A2.66%5.22%4.11%P/E Ratio-0.439.1426.7820.05Price / SalesN/A255.59395.49116.44Price / CashN/A65.8538.2534.62Price / Book-0.056.546.874.61Net Income-$23.53M$143.51M$3.22B$248.19M7 Day Performance-14.82%5.60%5.69%2.56%1 Month Performance-11.06%10.06%12.66%16.18%1 Year Performance336.12%-0.86%18.01%8.16% Cingulate Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CINGCingulate2.4156 of 5 stars$3.33-8.0%$25.75+673.3%+358.3%$14.14MN/A-0.3920News CoverageAnalyst ForecastAnalyst RevisionVHAQViveon Health AcquisitionN/A$11.00flatN/A+10.0%$62.26MN/A0.002High Trading VolumePYRGFPyroGenesis CanadaN/A$0.33+1.9%N/A-22.7%$61.85M$9.14M-5.5290Gap UpACHLAchilles TherapeuticsN/A$1.48flatN/AN/A$60.83MN/A-0.90250ASRTAssertio2.0351 of 5 stars$0.62+0.9%$2.75+346.9%-34.0%$58.94M$124.96M-0.8420Analyst ForecastGap UpPDSBPDS Biotechnology1.595 of 5 stars$1.29+7.5%$9.00+597.7%-51.8%$58.92MN/A-1.1120Earnings ReportRPTXRepare Therapeutics2.78 of 5 stars$1.36flat$4.50+230.9%-60.6%$58.33M$53.48M-0.68180Positive NewsIMMXImmix Biopharma1.9874 of 5 stars$2.09flat$7.00+234.9%-16.3%$58.17MN/A-2.469News CoveragePositive NewsMGXMetagenomi1.3194 of 5 stars$1.55+2.6%$14.75+851.6%-74.6%$57.94M$52.30M-0.59236Gap UpADVMAdverum Biotechnologies3.8137 of 5 stars$2.71-3.6%$26.60+881.5%-69.7%$56.62M$1M-0.45190Analyst RevisionHigh Trading VolumeGANXGain Therapeutics1.9908 of 5 stars$1.92-1.0%$8.20+327.1%-23.9%$56.50M$50,000.00-1.7520News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionGap Up Related Companies and Tools Related Companies Viveon Health Acquisition Competitors PyroGenesis Canada Competitors Achilles Therapeutics Competitors Assertio Competitors PDS Biotechnology Competitors Repare Therapeutics Competitors Immix Biopharma Competitors Metagenomi Competitors Adverum Biotechnologies Competitors Gain Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CING) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredMassive new energy source found in UtahNEW THIS WEEK: Huge Energy Discovery In Utah The Department of Energy say it could power America for millio...Stansberry Research | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cingulate Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cingulate With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
